Unlike Elon Musk's brain-computer interface, Synchron's doesn't require open-skull surgery, and it has an OpenAI chatbot baked in.
The US almost lost its measles elimination status once. Lessons from that episode suggest it will be more difficult to avoid doing so now.
Nearly 12 million people could lose health care coverage if the bill gets passed and signed by Trump, while hospitals would be hit hard by Medicaid cuts.
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.
In United States v. Skrmetti, the Supreme Court ruled that Tennessee’s ban on gender-affirming care for minors was not unconstitutional—the first case of its kind on which the court has ruled.
An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.
House Democrats sent letters to the potential buyers of the genetic testing company, asking how they plan to protect customer genetic data under a change of ownership.
So-called “less-lethal” weapons like those that have been used against demonstrators in Los Angeles can cause severe, lasting harm like nerve or brain damage or blindness. They can also kill.
Paradromics, a brain-computer interface startup, inserted its brain implant in a person—briefly—in an early test of its technology.
Scientists were able to create a bespoke treatment for KJ Muldoon’s rare genetic disorder within six months. It could be a blueprint for potentially life-saving, gene-editing Crispr therapies.